VC
Vivo Capital Portfolio holdings
AUM
$977M
This Quarter Return
+45.16%
1 Year Return
+209.68%
3 Year Return
+1,480.07%
5 Year Return
+2,591.98%
10 Year Return
–
AUM
$1.21B
AUM Growth
+$1.21B
(+12%)
Cap. Flow
-$133M
Cap. Flow
% of AUM
-11.02%
Top 10 Holdings %
Top 10 Hldgs %
77.54%
Holding
46
New
4
Increased
3
Reduced
10
Closed
3
Top Buys
| 1 |
ZBIO
Zenas BioPharma, Inc. Common Stock
ZBIO
|
$20M |
| 2 |
Corvus Pharmaceuticals
CRVS
|
$7.91M |
| 3 |
Terns Pharmaceuticals
TERN
|
$5.94M |
| 4 |
Trevi Therapeutics
TRVI
|
$5.39M |
| 5 |
Tenax Therapeutics
TENX
|
$721K |
Top Sells
| 1 |
Soleno Therapeutics
SLNO
|
$51.8M |
| 2 |
Aligos Therapeutics
ALGS
|
$29.5M |
| 3 |
Dyne Therapeutics
DYN
|
$18.7M |
| 4 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$16.9M |
| 5 |
Tarsus Pharmaceuticals
TARS
|
$15.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Soleno Therapeutics
SLNO
$3.6B
| $318M | 26.29% | 6,291,851 -1,025,000 | -14% | -$51.8M |
|
2
Geron
GERN
$893M
| $124M | 10.23% | 27,225,292 | – | – |
|
3
Harmony Biosciences
HRMY
$2.12B
| $104M | 8.63% | 2,606,247 | – | – |
|
|
VRNA
4
Verona Pharma
VRNA
$9.16B
| $102M | 8.45% | 3,549,758 | – | – |
|
|
SVA
5
DELISTED
Sinovac Biotech, Ltd
SVA
| $76.3M | 6.32% | 11,800,000 | – | – |
|
|
6
Terns Pharmaceuticals
TERN
$609M
| $57.5M | 4.76% | 6,895,746 +712,754 | +12% | +$5.94M |
|
7
Instil Bio
TIL
$182M
| $42M | 3.48% | 624,339 | – | – |
|
|
8
Dyne Therapeutics
DYN
$1.92B
| $40M | 3.31% | 1,114,960 -520,176 | -32% | -$18.7M |
|
9
Viridian Therapeutics
VRDN
$1.5B
| $38.2M | 3.16% | 1,678,207 | – | – |
|
|
AVDL
10
Avadel Pharmaceuticals
AVDL
$1.43B
| $35.2M | 2.91% | 2,684,109 -1,287,990 | -32% | -$16.9M |
|
|
SLN
11
Silence Therapeutics
SLN
$227M
| $20.1M | 1.66% | 1,105,454 | – | – |
|
|
ZBIO
12
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $20M | 1.66% | +1,183,260 | New | +$20M |
|
13
Erasca
ERAS
$445M
| $18.4M | 1.53% | 6,756,756 | – | – |
|
14
Olema Pharmaceuticals
OLMA
$375M
| $18M | 1.49% | 1,505,862 -367,842 | -20% | -$4.39M |
|
15
Astria Therapeutics
ATXS
$349M
| $17.1M | 1.41% | 1,552,685 -776,342 | -33% | -$8.55M |
|
16
Tourmaline Bio
TRML
$601M
| $15.2M | 1.26% | 591,882 | – | – |
|
17
Rezolute
RZLT
$619M
| $13.6M | 1.12% | 2,797,704 | – | – |
|
18
Oric Pharmaceuticals
ORIC
$994M
| $13.1M | 1.08% | 1,277,818 +8,142 | +0.6% | +$83.5K |
|
19
Sera Prognostics
SERA
$123M
| $12.9M | 1.07% | 1,650,440 | – | – |
|
20
Cogent Biosciences
COGT
$1.69B
| $12.1M | 1% | 1,122,471 -1,122,470 | -50% | -$12.1M |
|
21
Abeona Therapeutics
ABEO
$350M
| $11.6M | 0.96% | 1,842,751 | – | – |
|
|
CMPS
22
Compass Pathways
CMPS
$424M
| $10.1M | 0.84% | 1,608,000 | – | – |
|
23
Celcuity
CELC
$2.17B
| $9.1M | 0.75% | 610,500 | – | – |
|
24
Delcath Systems
DCTH
$385M
| $9M | 0.75% | 997,005 -669,741 | -40% | -$6.05M |
|
|
25
Corvus Pharmaceuticals
CRVS
$428M
| $7.91M | 0.65% | +1,497,268 | New | +$7.91M |
|